Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vulvovaginal Atrophy Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Evaluation of Fractional Bi-Polar Radio-Frequency for Symptoms of Vulvovaginal Atrophy

NCT05398172
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
MorpheusV Applicator
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Newport Beach, California • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal Atrophy

NCT02085980
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
Laser treatment
Device
Lead sponsor
El. En. SpA
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Palo Alto, California • West Chester, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Not applicable Interventional

Clinical Evaluation of Fractional Bi-Polar RF for Symptoms of SUI and Vulvovaginal Atrophy

NCT04705571
View directory record Official record
Conditions
Stress Urinary Incontinence, Vulvovaginal Signs and Symptoms
Interventions
MorpheusV Applicator
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Alpharetta, Georgia • Bluffton, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 24, 2026, 11:30 AM EDT
Completed No phase listed Observational

Vulvovaginal Atrophy Questionnaire (VVAQ): Psychometric Validation of a Novel PROM

NCT04746456
View directory record Official record
Conditions
Vulvovaginal Atrophy, Menopause, Genitourinary Syndrome of Menopause
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women

NCT01816139
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
Vehicle, WC3011 Estradiol Vaginal Cream
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
48
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Phase 3 Interventional

A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

NCT00196378
View directory record Official record
Conditions
Menopause
Interventions
Synthetic Conjugated estrogens, B, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
38
States / cities
Huntsville, Alabama • Tucson, Arizona • Carmichael, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2013 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Combination of BTL-785F and HPM-6000UF Devices for Women's Intimate Wellness

NCT06846216
View directory record Official record
Conditions
Vulvovaginal Atrophy, Urinary Incontinence, Sexual Dysfunction
Interventions
Treatment with BTL-785F and HPM-6000UF Devices
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
30 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Mission Viejo, California • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Not applicable Interventional

Randomized, Controlled Trial With Hybrid Fractional Laser

NCT03647189
View directory record Official record
Conditions
Vaginal Atrophy, Sexual Dysfunction, Vaginal Dryness, Dyspareunia
Interventions
Hybrid Fractional Laser
Device
Lead sponsor
Sciton
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 24, 2026, 11:30 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fractional Handpiece With CO2 Laser: Fractional Ablative Laser Treatment of Vulvovaginal Atrophy

NCT03271944
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
CO2 Laser Treatment
Device
Lead sponsor
SHERRY Thomas
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Agoura Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Phase 4 Interventional Results available

Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA

NCT02784613
View directory record Official record
Conditions
Vulvovaginal Atrophy, Dyspareunia
Interventions
Ospemifene
Drug
Lead sponsor
Sue Goldstein
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 24, 2026, 11:30 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment

NCT03682601
View directory record Official record
Conditions
Sexual Pain Disorders, Postmenopausal Symptoms, Vulvovaginal Atrophy, Female Sexual Dysfunction, Dyspareunia, Vulvodynia, Vestibulodynia, Arousal Disorders, Sexual, Genito-Pelvic Pain/Penetration Disorder, Female Sexual Arousal Disorder
Interventions
5% sinecatechins ointment, Placebo, 10% sinecatechins ointment
Drug
Lead sponsor
GTO Pharmaceutical, LLC
Other
Eligibility
20 Years to 70 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
New York, New York • Nyack, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Phase 3 Interventional Results available

Evaluate Long-Term Safety and Efficacy WC3011 (Estradiol Vaginal Cream)

NCT01455597
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
WC3011 Estradiol Vaginal Cream
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
64
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Not applicable Interventional Results available

Women's Interventions for Sexual Health: WISH

NCT05692960
View directory record Official record
Conditions
Sexual Dysfunction, Physiological, Body Image, Libido; Loss, Aversion
Interventions
Hypnotic Relaxation Intervention (HRI), Vulvovaginal Atrophy (VVA)
Other · Device
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 24, 2026, 11:30 AM EDT
Completed No phase listed Observational

High Tone Pelvic Floor Dysfunction

NCT03083262
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
no intervention
Other
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia

NCT01845649
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
WC3011 Estradiol Vaginal Cream, Vehicle
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 24, 2026, 11:30 AM EDT
Not listed Phase 3 Interventional

Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy

NCT03782480
View directory record Official record
Conditions
Menopause, Genitourinary Syndrome of Menopause, Vulvovaginal Atrophy, Menopause Syndrome, Dyspareunia
Interventions
Intrarosa, Placebos
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy

NCT00361569
View directory record Official record
Conditions
Menopause
Interventions
DR-2041a, DR-2041b, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
97
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 24, 2026, 11:30 AM EDT
Recruiting Phase 2 Interventional

Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women

NCT06197568
View directory record Official record
Conditions
Vulvo Vaginal Atrophy (VVA)
Interventions
Lasofoxifene Tartrate
Drug
Lead sponsor
Azure Biotech Inc.
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women

NCT01400776
View directory record Official record
Conditions
Postmenopausal Vulvovaginal Atrophy
Interventions
WC3011 Estradiol Vaginal Cream, Vehicle
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
70
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects

NCT02747641
View directory record Official record
Conditions
Atrophy, Vaginal Atrophy, Genital Diseases, Female
Interventions
Pixel CO2 Laser System
Procedure
Lead sponsor
Alma Lasers Inc.
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy

NCT02670785
View directory record Official record
Conditions
Vulvovaginal Atrophy, Menopause, Dyspareunia
Interventions
Estradiol Vaginal Capsule (EVC), Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Tucson, Arizona • San Diego, California • New London, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Phase 2 Interventional Results available

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

NCT02449902
View directory record Official record
Conditions
Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
Interventions
Estradiol, placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Phase 3 Interventional Results available

Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

NCT02013544
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, Prasterone (DHEA)
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 80 Years · Female only
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 24, 2026, 11:30 AM EDT
Completed Phase 4 Interventional

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

NCT03568604
View directory record Official record
Conditions
Dyspareunia
Interventions
Prasterone
Drug
Lead sponsor
San Diego Sexual Medicine
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 24, 2026, 11:30 AM EDT